论文部分内容阅读
目的:观察糖耐量减低(IGT)患者应用二甲双胍降糖治疗前后血清C反应蛋白(CRP)水平变化。方法:口服75 g葡萄糖耐量试验(OGTT)筛选出糖耐量正常(NGT) 1 5例,IGT4 5例,对4 5例IGT患者进行为期2 0周的随机、双盲、安慰剂对照、二甲双胍(1 . 5 g/d)干预治疗试验。血清CRP采用数率散射比浊法测定。结果:(1 )IGT患者血清CRP水平比NGT明显增高,分别为(5. 89±0 . 5 2 )和(4 72±0 6 5 )mg/L(P <0 . 0 1 )。(2 )在IGT患者,应用二甲双胍治疗2 0周后,血清CRP水平从5 . 99±0 . 82mg/L下降到4 . 78+0 43mg/L(P <0 . 0 5 ) ,对照组从5 . 92±0 85mg/L下降到5 .72±0 . 6 8mg/L(P >0 . 0 5 )。结论:①糖耐量减低时,血清CRP水平已经开始升高;②在IGT患者,应用二甲双胍降糖治疗后,随着糖代谢的改善,血清CRP水平也下降。
Objective: To observe the changes of serum C-reactive protein (CRP) levels in patients with impaired glucose tolerance (IGT) before and after treatment with metformin. Methods: A total of 45 patients with IGT were randomized, double-blind, placebo-controlled and treated with metformin (25 cases of normal glucose tolerance test (OGTT) 1.5 g / d) intervention trial. Serum CRP was determined by rate nephelometry. Results: (1) Serum levels of CRP in IGT patients were significantly higher than those in NGT patients (5.89 ± 0.52) and (4272 ± 0.55) mg / L, respectively (P <0.01). (2) In patients with IGT, serum CRP level decreased from 5.99 ± 0.82mg / L to 4.78 + 0 43mg / L (P <0.05) after treatment with metformin for 20 weeks. The control group from 5.92 ± 0 85mg / L decreased to 5.72 ± 0.68mg / L (P> 0.05). Conclusion: ① When CRP level is lower, serum CRP level has begun to increase. ② In patients with IGT, the serum CRP levels decrease with the improvement of glucose metabolism after metformin hypoglycemic treatment.